Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1% - similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion. The device's strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.

Original languageEnglish (US)
Pages (from-to)45-58
Number of pages14
JournalInternational Journal of Women's Health
Volume1
Issue number1
StatePublished - 2009

Fingerprint

Levonorgestrel
Patient Safety
Contraceptive Agents
Intrauterine Devices
Pregnancy Rate
Contraception
Adenomyosis
Endometrial Hyperplasia
Menorrhagia
Tubal Sterilization
Dysmenorrhea
Estrogen Replacement Therapy
Life Tables
Leiomyoma
Endometriosis
Endometrium
Fertility
Steroids
Hemorrhage
Equipment and Supplies

Keywords

  • Intrauterine device
  • IUD
  • IUS
  • Levonorgestrel intrauterine system
  • LNG-IUS

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Maternity and Midwifery

Cite this

@article{a5c1a3fce7694e4882fc87de997dd353,
title = "Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS",
abstract = "Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1{\%} - similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15{\%} to 20{\%} of women become amenorrheic 1 year after insertion. The device's strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.",
keywords = "Intrauterine device, IUD, IUS, Levonorgestrel intrauterine system, LNG-IUS",
author = "Paula Bednarek and Jeffrey Jensen",
year = "2009",
language = "English (US)",
volume = "1",
pages = "45--58",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS

AU - Bednarek, Paula

AU - Jensen, Jeffrey

PY - 2009

Y1 - 2009

N2 - Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1% - similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion. The device's strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.

AB - Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1% - similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion. The device's strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.

KW - Intrauterine device

KW - IUD

KW - IUS

KW - Levonorgestrel intrauterine system

KW - LNG-IUS

UR - http://www.scopus.com/inward/record.url?scp=77953365458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953365458&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953365458

VL - 1

SP - 45

EP - 58

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

IS - 1

ER -